Aminolevulinic acid - SonALAsense
Alternative Names: 5-ALA - SonALAsense; 5-Aminolevulinic acid - SonALAsense; SONALA-001Latest Information Update: 13 Aug 2024
At a glance
- Originator SonALAsense
- Developer SonALAsense; The Ivy Brain Tumor Center
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma; Glioma
- Preclinical Cancer
Most Recent Events
- 02 Aug 2024 SonALAsense terminates a phase II trial in Glioma (In children, In adolescents, In adults, In the elderly) in USA (IV), due to lack of funding but not due to safety concerns (NCT05123534)
- 08 Jul 2024 SonALAsense terminates a phase-II trial in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) due to funding challenges (NCT05370508)
- 31 May 2024 Efficacy and adverse events data from a phase 0/I trial in glioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)